Video

Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

Author(s):

Julie M. Vose, MD
Conference|International Conference on Malignant Lymphoma

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center, discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

As single agents, both acalabrutinib and pembrolizumab have shown activity in other types of lymphoma and their toxicities do not overlap. This makes them the combination of choice for patients with relapsed/refractory DLBCL, Vose explains.

She says that despite the low complete response rate and short duration of response seen overall in the study, several patients showed meaningful activity (>24 months) and the combination was well tolerated. This is rationale to explore the combination further.

<<< 15th International Conference on Malignant Lymphoma

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Related Content
Kenneth W. Merrell, MD
October 9th 2024

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Armin Ghobadi, MD, of the Washington University School of Medicine
October 7th 2024

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Kristin A. Higgins, MD, chief clinical officer, City of Hope Cancer Center Atlanta
October 6th 2024

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29